Evidence check: Pharmakogenetik Medicheck in the context of longevity

The Pharmacogenetics Medicheck analyzes genetic variants affecting drug metabolism (e.g., CYP2D6, CYP2C19, SLCO1B1). In the context of longevity, direct evidence is weak: no randomized trials show that such a test extends lifespan. However, pharmacogenetics can help older adults avoid adverse drug reactions – an indirect benefit for healthspan. Evidence for the clinical validity of tested SNPs is moderate (human studies, but often small effect sizes). Important: This test does not replace medical advice; dose adjustments should only be made by qualified professionals. Moreover, many drug-gene interactions are not yet sufficiently proven. For an evidence-based longevity strategy, lifestyle factors (diet, exercise, sleep) are far more relevant than a single genetic test.